REG - Physiomics PLC - Physiomics Awarded New Contract by Numab

PhysiomicsAnnouncement

14/04/2026 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260414:nRSN2670Aa&default-theme=true

RNS Number : 2670A  Physiomics PLC  14 April 2026

14 April 2026

 

Physiomics plc

("Physiomics" or the "Company")

 

Physiomics Awarded New Contract by Numab Therapeutics

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce a new contract with
its valued and long-standing client, Numab Therapeutics AG ("Numab
Therapeutics").

Numab Therapeutics is a biopharmaceutical company focused on the discovery and
development of next-generation multispecific antibody-based therapeutics for
inflammation and oncology. Under this new contract, Physiomics will develop a
mechanistic pharmacokinetic-pharmacodynamic (PK/PD) modelling framework to
support proof-of-concept activities for a new programme within Numab
Therapeutics' oncology pipeline.

Throughout the project, Physiomics will apply quantitative approaches to
interpret emerging data, optimise experimental design and development
strategy, and inform key go/no-go decision-making. The project is expected to
commence in April 2026 and complete in Q3 2026.

This project further strengthens Physiomics' established collaboration with
Numab Therapeutics and highlights the ongoing integration of model-informed
approaches to support strategic decision-making across Numab Therapeutics'
pipeline.

Dr Peter Sargent, CEO of Physiomics, commented:

"We are thrilled to extend our collaboration with Numab Therapeutics to
provide insights that can support robust proof-of-concept decision-making for
this early oncology programme."

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep
biology expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all
relevant and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and clinical
studies. Through use of cutting-edge computational
tools, bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 140 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics &
CRUK.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTFLFIRSDIVLIR



            Copyright 2019 Regulatory News Service, all rights reserved